Bottom line is that the recurring revenue fro contracts won to date has still not been fully realised and there is a pipeline of contacts likely to be won
Yes the PE is still off the chart but the revenue growth looks likely to continue onwards and upwards and EBIT margin of 50% is attractive.
- Forums
- ASX - By Stock
- PME
- Ann: Company Announcement - Interim Results
Ann: Company Announcement - Interim Results, page-23
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PME (ASX) to my watchlist
(20min delay)
|
|||||
Last
$204.72 |
Change
0.090(0.04%) |
Mkt cap ! $21.20B |
Open | High | Low | Value | Volume |
$201.52 | $205.24 | $200.90 | $29.12M | 142.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $204.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$204.89 | 130 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4 | 204.720 |
1 | 50 | 204.500 |
1 | 3 | 204.400 |
1 | 43 | 204.280 |
1 | 439 | 204.220 |
Price($) | Vol. | No. |
---|---|---|
204.890 | 130 | 1 |
205.250 | 439 | 1 |
205.280 | 111 | 1 |
205.480 | 439 | 1 |
205.500 | 200 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
PME (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online